About RestorGenex Corp. (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Bio Therapeutic Drugs
- Symbol: NASDAQ:DFFN
- CUSIP: N/A
- Web: www.diffusionpharma.com
- Current Ratio: 0.60%
- Quick Ratio: 0.60%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $0.89 per share
- Price / Book: 1.52
- Trailing EPS: ($0.59)
- Net Income: ($18,030,000.00)
- Return on Equity: -403.38%
- Return on Assets: 40.33%
- Employees: 10
- Outstanding Shares: 14,520,000
Frequently Asked Questions for RestorGenex Corp. (NASDAQ:DFFN)
What is RestorGenex Corp.'s stock symbol?
RestorGenex Corp. trades on the NASDAQ under the ticker symbol "DFFN."
When will RestorGenex Corp. make its next earnings announcement?
Who are some of RestorGenex Corp.'s key competitors?
Some companies that are related to RestorGenex Corp. include Catabasis Pharmaceuticals (CATB), ContraVir Pharmaceuticals (CTRV), Avacta Group Plc (AVCT), Imprimis Pharmaceuticals (IMMY), Auris Medical Holding AG (EARS), Proteon Therapeutics (PRTO), Celsion Corporation (CLSN), Anthera Pharmaceuticals (ANTH), ANGLE plc (AGL), Pain Therapeutics (PTIE), Redx Pharma PLC (REDX), Zosano Pharma Corporation (ZSAN), Orexigen Therapeutics (OREX), Midatech Pharma PLC (MTPH), Vical Incorporated (VICL), Aviragen Therapeutics (AVIR), Kitov Pharmaceuticals Holdings (KTOV) and Xenetic Biosciences (XBIO).
How do I buy RestorGenex Corp. stock?
Shares of RestorGenex Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is RestorGenex Corp.'s stock price today?
One share of RestorGenex Corp. stock can currently be purchased for approximately $1.35.
How big of a company is RestorGenex Corp.?
RestorGenex Corp. has a market capitalization of $19.49 million. The company earns ($18,030,000.00) in net income (profit) each year or ($0.59) on an earnings per share basis. RestorGenex Corp. employs 10 workers across the globe.
How can I contact RestorGenex Corp.?
RestorGenex Corp.'s mailing address is 2020 Avon Ct Ste 4, CHARLOTTESVILLE, VA 22902-8734, United States. The company can be reached via phone at +1-434-2200718 or via email at [email protected]
MarketBeat Community Rating for RestorGenex Corp. (NASDAQ DFFN)MarketBeat's community ratings are surveys of what our community members think about RestorGenex Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for RestorGenex Corp. (NASDAQ:DFFN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for RestorGenex Corp. (NASDAQ:DFFN)
Analysts' Ratings History for RestorGenex Corp. (NASDAQ:DFFN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for RestorGenex Corp. (NASDAQ:DFFN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for RestorGenex Corp. (NASDAQ:DFFN)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for RestorGenex Corp. (NASDAQ:DFFN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for RestorGenex Corp. (NASDAQ DFFN)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for RestorGenex Corp. (NASDAQ DFFN)
Financials are not available for this stock.
RestorGenex Corp. (NASDAQ DFFN) Chart for Saturday, November, 18, 2017